$45.78—Stale · unknown old
NASDAQ • Last print unknown ago
$45.78—Stale · unknown old
F/M Emerald Life Sciences Innovation ETF (LFSC) focuses on investing in companies within the life sciences sector, particularly those engaged in biotechnology, pharmaceuticals, and healthcare innovation. The ETF's strategy capitalizes on the growing demand for healthcare solutions driven by an aging population and increasing prevalence of chronic diseases.
LFSC generates revenue primarily through management fees based on the total assets under management. The ETF's focus on life sciences provides a unique angle, as it targets high-growth sectors that are less correlated with traditional market cycles, allowing for potential alpha generation.
Performance of underlying life sciences stocks in the ETF's portfolio
Changes in investor sentiment towards healthcare and biotech sectors
Regulatory developments impacting the life sciences industry
Market volatility affecting ETF inflows and outflows
Regulatory changes affecting drug approvals and healthcare policies
Technological disruption in healthcare delivery and pharmaceuticals
Increased competition from other healthcare-focused ETFs
Market volatility affecting investor appetite for niche ETFs
Liquidity risk associated with rapid redemptions from the ETF
Market risk from fluctuations in the value of underlying securities
moderate - The ETF's performance is somewhat tied to economic cycles, as healthcare spending can be resilient during downturns but may be affected by broader market trends.
Rising interest rates could lead to higher borrowing costs for biotech firms, potentially impacting their valuations and the ETF's performance.
minimal
growth - Investors seeking exposure to high-growth sectors like biotechnology and healthcare innovation.
moderate - The ETF may exhibit moderate volatility due to the nature of its underlying assets.